drugset / Trial / NCT01613040
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
RandomizedParallel-groupDouble-blind
Summary
This multiple-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, parallel group study will investigate the effect of RO4917838 on the QTc interval in healthy volunteers. Healthy volunteers will be randomized to one of 4 treatment arms; Arm A: low dose of RO4917838, Arm B: high dose of RO4917838, Arm C: placebo to RO4917838 and moxifloxacin on Day 1, Arm D: placebo to RO4917838 and moxifloxacin on Day 11. The anticipated time on study treatment is 11 days.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | bitopertin | Small molecule | 30 mg | Oral |
| Subject | bitopertin | Small molecule | 175 mg | Oral |
Indications
No indication recorded.